Optimizing therapy in pediatric acute lymphoblastic leukemia (ALL ): the crucial role of monitoring 6-mercaptopurine metabolites

Acute lymphoblastic leukemia (ALL) is the most prevalent form of cancer in children, and maintenance therapy with 6-mercaptopurine (6-MP) is crucial for treating these patients. While many patients respond well to treatment, some fail to achieve the desired therapeutic outcomes. This can occur for a variety of reasons, including ineffective metabolism of 6-MP. The drug is metabolized into thioguanine nucleotides (6-TGN), the active metabolites responsible for myelosuppression, and 6-methylmercaptopurine ribonucleotides (6-MMPR), which are linked to hepatotoxicity and gastrointestinal toxicity. Therapeutic failure in certain patients may necessitate dosage increases, thus raising the risk of adverse effects, such as myelosuppression and hepatotoxicity. This paper emphasizes the significance of monitoring 6-MP metabolites as a supportive strategy to optimize therapy for pediatric ALL patients, which is typically guided by adjustments in leukocyte count, white blood cells. Measuring 6-TGN and 6-MMPR provides a valuable tool for more precise and personalized patient management, allowing clinicians to initiate treatment with lower dosages in patients presenting elevated levels of 6-MMPR. This monitoring approach not only enhances long-term prognoses but also reduces the likelihood of adverse effects.